The oncology department, Xiangtan Central Hospital, Hunan, China.
The Medical Department, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, 210002, China.
Invest New Drugs. 2023 Jun;41(3):532-538. doi: 10.1007/s10637-023-01363-6. Epub 2023 Apr 26.
Hepatocellular carcinoma ranks fourth in cancer-related causes of death worldwide and second in China. Patients with hepatocellular carcinoma (HCC) at the early stage have a better prognosis compared to HCC patients at the late stage. Therefore, early screening for HCC is critical for clinical treatment decisions and improving the prognosis of patients. Ultrasound (US), computed tomography (CT), and serum alpha fetoprotein (AFP) have been used to screen HCC, but HCC is still difficult to be diagnosed in the early stage due to the low sensitivity of the above methods. It is urgent to find a method with high sensitivity and specificity for the early diagnosis of HCC. Liquid biopsy is a noninvasive detection method using blood or other bodily fluids. Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are important biomarkers for liquid biopsy. Recently, HCC screening methods using the application of cfDNA and ctDNA have become the hot spot of early HCC diagnostics. In this mini review, we summarize the latest research progress of liquid biopsy based on blood cfDNA in early screening of HCC.
肝细胞癌（HCC）在全球癌症相关死亡原因中排名第四，在中国排名第二。与晚期 HCC 患者相比，早期 HCC 患者的预后更好。因此，早期筛查 HCC 对于临床治疗决策和改善患者预后至关重要。超声（US）、计算机断层扫描（CT）和血清甲胎蛋白（AFP）已被用于筛查 HCC，但由于上述方法的灵敏度较低，HCC 仍难以在早期诊断。迫切需要找到一种具有高灵敏度和特异性的方法来早期诊断 HCC。液体活检是一种使用血液或其他体液进行的非侵入性检测方法。无细胞 DNA（cfDNA）和循环肿瘤 DNA（ctDNA）是液体活检的重要生物标志物。最近，使用 cfDNA 和 ctDNA 应用的 HCC 筛查方法已成为早期 HCC 诊断的热点。在这篇迷你综述中，我们总结了基于血液 cfDNA 的液体活检在早期筛查 HCC 方面的最新研究进展。
